Key facts
- Luxna Biotech’s last known valuation is $8.9M (Aug 2025).
- It has raised $20.2M; the latest was Later Stage VC ($2.6M) in Aug 2025.
- Notable investors include Mitsubishi UFJ Capital, Mizuho Capital, J-Startup, Japan Finance Corporation, Nippon Venture Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Luxna Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Luxna Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Luxna Biotech
Operator of a biotechnology company intended to promote safe and effective oligonucleotide therapeutics. The company's drugs are based on a licensed cross-linked modified nucleic acid group and are safe because they bind strongly to the target mRNA, obtain efficacy, and reduce the risk of hepatotoxicity, enabling hospitals to provide effective alternatives to patients who fight diseases without effective drugs.
- Sector
- Healthcare
- HQ
- Suita, Japan
- Founded
- 2017
- Employees
- 21
- Website
- luxnabiotech.co.jp/
- Ownership
- Privately Held (backing)
Luxna Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Luxna Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Luxna Biotech in its N-PORT filings yet. We sweep new filings monthly.